Analyst firms · Morgan Stanley · CRL
Morgan Stanley CRL price target and rating history
Charles River Laboratories International Inc. (CRL) · Health Care
Morgan Stanley rates Charles River Laboratories International Inc. (CRL) Overweight with a $220 price target, as of its latest action on Jun 17, 2026. It has published 4 rating actions on CRL since November 2021, including 1 upgrade and 1 downgrade. Across 5 firms with a CRL price target in the last 12 months, the median target is $220. Morgan Stanley's target matches it.
- Current rating
- Overweight
- Price target
- $220
- Median target, all firms
- $220
- Actions on CRL
- 4
Morgan Stanley price target on CRL
Every Morgan Stanley rating on CRL
- Jun 17, 2026
- Aug 4, 2022
- Feb 17, 2022
- Nov 4, 2021
How other firms rate CRL
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Buy | $357 | Sep 30, 2026 |
| CLSA | Hold | $219 | Jul 20, 2026 |
| Morgan Stanley | Overweight | $220 | Jun 17, 2026 |
| RBC Capital Markets | Outperform | $215 | Apr 14, 2026 |
| BofA Securities | Buy | $225 | Dec 15, 2025 |
| Argus Research | Buy | Nov 17, 2025 |
Questions about Morgan Stanley and CRL
- What is Morgan Stanley's price target for CRL?
- Morgan Stanley's latest stated price target for Charles River Laboratories International Inc. (CRL) is $220, from its action on Jun 17, 2026.
- What is Morgan Stanley's rating on CRL?
- Morgan Stanley rates CRL Overweight, a bullish rating, as of Jun 17, 2026.
- When did Morgan Stanley last change its view on CRL?
- On Jun 17, 2026, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $220.
- How does Morgan Stanley's CRL target compare with other analysts?
- Across 5 firms with a CRL price target in the last 12 months, the median target is $220. Morgan Stanley's target matches it.
More CRL rating histories
All Morgan Stanley ratingsCRL news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.